Slingshot Insights | Crvs Overview

CRVS Overview

Upcoming Projects (CRVS)

Assessing five-year Phase 2b KEYNOTE-942 results for intismeran autogene plus pembrolizumab in resected high-risk melanoma
Tickers: MRK, MRNA, CRVS
Execute By: Dec 31, 2026

Expired Projects (CRVS)

Assessing Phase 1 Results for Soquelitinib in Moderate to Severe Atopic Dermatitis from Corvus Pharmaceuticals
Ticker: CRVS
Execute By: Dec 31, 2025
Discussing the potential of Corvus’ CPI-006 anti-CD73 antibody in treating advanced refractory cancer
Ticker: CRVS
Execute By: Oct 04, 2019

Upcoming & Overdue Catalysts (CRVS)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (CRVS)

Corvus Pharma's (CRVS) Phase 1b/2 Clinical Trial of Lead Prostate-Cancer Drug Ciforadenant Presented at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium
Ticker: CRVS
Occurred on: Feb 13, 2020
Updated Clinical Data from Corvus Pharma's (CRVS) Phase 1/1b Clinical Trial of CPI-818 ITK-inhibitor Presented at the 12th Annual T-Cell Lymphoma Forum
Ticker: CRVS
Occurred on: Feb 01, 2020

Strategic Initiatives (CRVS)

Don’t see a strategic initiative related to the company you care about? Create your own!